94 related articles for article (PubMed ID: 11523314)
1. Phenotype of cytochrome P450 CYP2D6 in patients with familial adenomatous polyposis.
Slanar O; Perlík F; Jirásek V
Methods Find Exp Clin Pharmacol; 2001 Apr; 23(3):145-7. PubMed ID: 11523314
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
3. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
4. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
Pedersen RS; Damkier P; Brosen K
Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
[TBL] [Abstract][Full Text] [Related]
5. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Brosens LA; Iacobuzio-Donahue CA; Keller JJ; Hustinx SR; Carvalho R; Morsink FH; Hylind LM; Offerhaus GJ; Giardiello FM; Goggins M
Clin Cancer Res; 2005 Jun; 11(11):4090-6. PubMed ID: 15930344
[TBL] [Abstract][Full Text] [Related]
6. Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma.
Paar WD; Schuhler H; Fimmers R; Dengler HJ
Eur J Clin Pharmacol; 1989; 36(6):555-60. PubMed ID: 2590312
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients.
Lohmann PL; Rao ML; Ludwig M; Griese EU; Zanger UM; Mörike K; Maier W; Bagli M
Eur J Clin Pharmacol; 2001 Jul; 57(4):289-95. PubMed ID: 11549206
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population.
Niewinski P; Orzechowska-Juzwenko K; Hurkacz M; Rzemislawska Z; Jaźwinska-Tarnawska E; Milejski P; Forkasiewicz Z
Eur J Clin Pharmacol; 2002 Nov; 58(8):533-5. PubMed ID: 12536989
[TBL] [Abstract][Full Text] [Related]
9. Caffeine phenotyping of cytochrome P4501A2, N-acetyltransferase, and xanthine oxidase in patients with familial adenomatous polyposis.
Spigelman AD; Farmer KC; Oliver S; Nugent KP; Bennett PN; Notarianni LJ; Dobrocky P; Phillips RK
Gut; 1995 Feb; 36(2):251-4. PubMed ID: 7883225
[TBL] [Abstract][Full Text] [Related]
10. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
Bozkurt A; Basçi NE; Işimer A; Sayal A; Kayaalp SO
Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895
[TBL] [Abstract][Full Text] [Related]
11. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol.
Paar WD; Poche S; Gerloff J; Dengler HJ
Eur J Clin Pharmacol; 1997; 53(3-4):235-9. PubMed ID: 9476037
[TBL] [Abstract][Full Text] [Related]
12. Sparteine oxidation polymorphism in Greenlanders living in Denmark.
Brøsen K
Br J Clin Pharmacol; 1986 Oct; 22(4):415-9. PubMed ID: 3768256
[TBL] [Abstract][Full Text] [Related]
13. Sparteine oxidation polymorphism in Denmark.
Brøsen K; Otton SV; Gram LF
Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
[TBL] [Abstract][Full Text] [Related]
14. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
15. Sparteine oxidation polymorphism: a family study.
Brøsen K; Otton SV; Gram LF
Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
[TBL] [Abstract][Full Text] [Related]
16. Oxidative phenotype polymorphism (P450 2D6) and metabolism of toluene.
Pelclová D; Mráz J; Patzelová V; Pícková J; Pospísil J; Vodicková L; Hornychová M; Vejlupková J
Int J Clin Pharmacol Ther; 1996 Jan; 34(1):38-42. PubMed ID: 8688995
[TBL] [Abstract][Full Text] [Related]
17. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.
Jazwinska-Tarnawska E; Orzechowska-Juzwenko K; Niewinski P; Rzemislawska Z; Loboz-Grudzien K; Dmochowska-Perz M; Slawin J
Int J Clin Pharmacol Ther; 2001 Jul; 39(7):288-92. PubMed ID: 11471772
[TBL] [Abstract][Full Text] [Related]
18. Small-intestinal involvement in familial adenomatous polyposis: evaluation by double-balloon endoscopy and intraoperative enteroscopy.
Matsumoto T; Esaki M; Yanaru-Fujisawa R; Moriyama T; Yada S; Nakamura S; Yao T; Iida M
Gastrointest Endosc; 2008 Nov; 68(5):911-9. PubMed ID: 18561922
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
20. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.
Woolhouse NM; Eichelbaum M; Oates NS; Idle JR; Smith RL
Clin Pharmacol Ther; 1985 May; 37(5):512-21. PubMed ID: 3987174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]